目前,甲基强的松龙(Methylprednisolone,MP)冲击治疗多用于经足量强的松口服8周病情无缓解的难治性肾病患儿,对部分初发的儿童原发性肾病综合征早期进行MP冲击治疗,以缩短病程,减少难治性肾病的发生率报道甚少。本文通过对部分初发而临床症状较重的儿童肾病,在诱导阶段早期采用MP冲击治疗,并进行追踪观察,探讨MP冲击治疗的应用时机以及对本病预后的影响,现报告如下。 At present, the treatment of methylprednisolone (MP) is mostly used in children with refractory nephropathy who have been treated with prednisone for 8 weeks without remission. Some children with primary nephrotic syndrome MP impact therapy to shorten the course of the disease and reduce the incidence of refractory nephropathy rarely reported. In this paper, part of the onset of clinical symptoms of children with severe nephropathy in the induction phase of the early use of MP impact therapy, and follow-up observation of the impact of the MP impact of the timing of the treatment and the prognosis of the disease, are as follows.